PROTON RISING: A NEW ERA OF ACCESS, QUALITY, AND CLINICAL EXCELLENCE

San Francisco – September 26, 2025 – Mevion Medical Systems invites attendees of ASTRO 2025 to celebrate a breakthrough in cancer care with the showcase of the newly FDA-cleared MEVION S250-FIT™, the world’s first proton therapy system designed to fit seamlessly into existing LINAC vaults.

The FIT™ system is already in deployment at premier institutions, including Stanford Health Care, BayCare Health System, Atlantic Health System, and University of Nebraska. Most recently, Loma Linda University Health, home to the world’s first hospital-based proton center, has signed on to adopt the S250-FIT system, marking the beginning of the next era of care at this historic institution.

For the first time, ASTRO attendees can see, hear, and experience FIT on the show floor and through scientific, clinical, and educational programming:

Experience the System Firsthand

Stanford Symposium & Site Tour: On Saturday, September 27, join the Stanford Modern Proton Radiation Oncology Symposium for an exclusive tour of the Stanford Medicine Cancer Center, featuring the world’s first proton system in a conventional radiotherapy vault.

Live at Booth #1215: Explore the full-scale MEVION S250-FIT system in person, the only proton therapy platform designed for installation in a standard LINAC vault. Attendees can step inside the future of vault-based proton therapy and see how FIT is bringing advanced cancer care within reach for more clinics and patients.

Learn from the Experts

Clinical Insights with DirectARC™: On Sunday, September 28 at 3:30 PM, Dr. Mark Newpower (University of Oklahoma) will present at the RaySearch Booth #20025, sharing treatment planning results for bilateral head and neck cancer using DirectARC. Attendees will hear how FIT technology enhances dose shaping and improves organ-at-risk sparing.

Engage with the Science

Poster Presentation #2189: Researchers from Massachusetts General Hospital and Mevion will present “A Treatment Planning Study of a New Fixed Beamline Model for an Upright Compact Proton Therapy System.” The study showcases treatment planning quality for prostate, breast, liver, and head and neck cancers using the MEVION S250-FIT system.

Designed to bring proton therapy where it was once unimaginable, the MEVION S250-FIT enables full-spectrum treatment capabilities in a compact footprint. With advanced image guidance, diagnostic-quality CT at isocenter, and support for innovations like DirectARC™, FLASH* research, and adaptive proton therapy, FIT sets a new benchmark for access, precision, and clinical versatility.

“Our goal with FIT is simple: to make high-quality proton therapy accessible without compromise,” said Tina Yu, CEO of Mevion Medical Systems. “By removing infrastructure barriers and delivering advanced proton capabilities in a compact form, now with the strength of FDA clearance and advanced clinical tools, we are empowering institutions to bring the future of cancer care to their communities.”

Join us at ASTRO 2025, Booth #1215, to celebrate this new chapter in proton therapy—where innovation meets accessibility and a new era of care takes place.

About Mevion Medical Systems
Mevion Medical Systems is the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion compact proton therapy single-room systems have been used by leading cancer centers for treating patients. Mevion’s series of products, including the flagship MEVION S250i and MEVION S250-FIT with HYPERSCAN pencil beam scanning, represent the world’s most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Massachusetts with a presence in Europe and Asia. For more information, please visit www.mevion.com.

*For research use only and requires additional evaluation prior to use.

Media Contacts:

Jacqueline Abner-Pongratz
Mevion Medical Systems
Jacqueline.Pongratz@Mevion.com